Enzon Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 61

Enzon Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Enzon Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Enzon Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Enzon Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Enzon Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Enzon Pharmaceuticals, Inc. - Brief Enzon Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Enzon Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Enzon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Enzon Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Enzon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Enzon Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Enzon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Enzon Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Enzon Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc. - Key Therapeutics; Enzon Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Enzon Pharmaceuticals, Inc. - News; Enzon Pharmaceuticals, Inc. - Latest Updates; Enzon Pharmaceuticals, Inc. - Pipeline; Enzon Pharmaceuticals, Inc. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 5
Enzon Pharmaceuticals, Inc. Snapshot 6
Enzon Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Enzon Pharmaceuticals, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Enzon Pharmaceuticals, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Enzon Pharmaceuticals, Inc. – Pipeline Products Glance 12
Enzon Pharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Enzon Pharmaceuticals, Inc. – Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Enzon Pharmaceuticals, Inc. – Drug Profiles 15
EZN-2968 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Phase I - Trial Details 15
EZN-4176 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Research and Development Brief 16
Licensing and Collaboration 16
Discovery/Preclinical Trial Details 16
EZN3920 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PEG-SN38 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PEG-SN38 + Avastin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PEG-SN38 + Cetuximab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Enzon Pharmaceuticals, Inc. – Pipeline Analysis 24
Enzon Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 24
Enzon Pharmaceuticals, Inc. – Pipeline Products By Target 25
Enzon Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 26
Enzon Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 27
Enzon Pharmaceuticals, Inc. – Recent Pipeline Updates 28
Enzon Pharmaceuticals, Inc. - Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
EZN-2232 31
ENZ-3042 31
Oncaspar + Gemzar 31
PEG-Paclitaxel 32
PEG-SN38 32
Prothecan 32
Enzon Pharmaceuticals, Inc. – Company Statement 33
Enzon Pharmaceuticals, Inc. – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Enzon Pharmaceuticals, Inc., Recent Developments 38
Enzon Pharmaceuticals, Inc.- Press Release 38
Jun 19, 2012: Enzon Pharma Announces Data From Phase I Study of PEG-SN38 In Pediatric Neuroblastoma And Other Solid Tumors Presented At 2012 Advances In Neuroblastoma Research Conference 38
Jun 04, 2012: Enzon Presents Final Analysis Of Phase II PEG-SN38 Study In Patients With Metastatic Breast Cancer At ASCO 2012 Annual Meeting 38
Financial Deals Landscape 40
Enzon Pharmaceuticals, Inc., Deals Summary 40
Enzon Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 41
Partnerships 41
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 41
Enzon Pharma Signs Agreement With Santaris Pharma 43
Enzon Pharma Extends Its Collaboration With Micromet 45
Bio-Rad Labs Enters Into An Agreement With Enzon Pharma 46
Licensing Agreements 47
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 47
Enzon Pharma Enters Into Licensing Agreement With NOF 48
Cambridge Antibody Enters Into Licensing Agreement With Enzon Pharma 49
Enzon Pharma Enters Into Licensing Agreement With NatImmune 50
Enzon Pharma Enters Into Agreement With Pharmagene 51
Enzon Pharma Enters Into Licensing Agreement With Inex Pharma 52
Debt Offering 54
Enzon Pharma Completes Private Placement Of $275 Million 54
Asset Transactions 56
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 56
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Enzon Pharmaceuticals, Inc., Key Information 6
Enzon Pharmaceuticals, Inc., Key Facts 6
Enzon Pharmaceuticals, Inc. – Pipeline by Indication, Select 8
Enzon Pharmaceuticals, Inc. – Pipeline by Stage of Development, Select 9
Enzon Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, Select 10
Enzon Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, Select 11
Enzon Pharmaceuticals, Inc. – Phase II, Select 12
Enzon Pharmaceuticals, Inc. – Phase I, Select 13
Enzon Pharmaceuticals, Inc. – Pre-Clinical, Select 14
Enzon Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, Select 24
Enzon Pharmaceuticals, Inc. - Pipeline By Target, Select 25
Enzon Pharmaceuticals, Inc. – Pipeline By Route of Administration, Select 26
Enzon Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, Select 27
Enzon Pharmaceuticals, Inc. – Recent Pipeline Updates, Select 28
Enzon Pharmaceuticals, Inc. - Discontinued Pipeline Products, Select 31
Enzon Pharmaceuticals, Inc., Other Locations 37
Enzon Pharmaceuticals, Inc., Subsidiaries 37
Enzon Pharmaceuticals, Inc., Deals Summary 40
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 41
Enzon Pharma Signs Agreement With Santaris Pharma 43
Enzon Pharma Extends Its Collaboration With Micromet 45
Bio-Rad Labs Enters Into An Agreement With Enzon Pharma 46
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 47
Enzon Pharma Enters Into Licensing Agreement With NOF 48
Cambridge Antibody Enters Into Licensing Agreement With Enzon Pharma 49
Enzon Pharma Enters Into Licensing Agreement With NatImmune 50
Enzon Pharma Enters Into Agreement With Pharmagene 51
Enzon Pharma Enters Into Licensing Agreement With Inex Pharma 52
Enzon Pharma Completes Private Placement Of $275 Million 54
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 56

List of Figures
Enzon Pharmaceuticals, Inc. – Pipeline by Indication, Select 8
Enzon Pharmaceuticals, Inc. – Pipeline by Stage of Development, Select 9
Enzon Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, Select 10
Enzon Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, Select 11
Enzon Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, Select 24
Enzon Pharmaceuticals, Inc. - Pipeline By Target, Select 25
Enzon Pharmaceuticals, Inc. – Pipeline By Route of Administration, Select 26
Enzon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, Select 27

Customers who bought this item also bought

• Idenix Pharmaceuticals, Inc.
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Ixia - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Kuehne and Nagel - IT Sales Opportunities - 2009
• Analysis of Google Inc
• eBay - Strong Execution